The Moderna Covid-19 vaccine being administered to Katie Podlaski at Duquesne University, Jan. 28 (Gene J. Puskar/AP Images)

Is it time to stock up on wine? This pan­dem­ic could stretch out — and that has some ma­jor mar­ket im­pli­ca­tions

Bern­stein an­a­lyst Ron­ny Gal has some good news and some bad news re­lat­ed to the pan­dem­ic.

So what do you want to hear first?

It’s the end of the week, so let’s start off on some­thing sweet be­fore we turn to the sour.

In Gal’s sea­soned opin­ion, there are pos­i­tive notes be­ing sound­ed in the fight against Covid-19. These new vari­ants, he writes, are still be­ing knocked back by the ap­proved vac­cines, and the mR­NA jabs from Mod­er­na and Pfiz­er/BioN­Tech demon­strat­ed enough of a knock­out punch against the Brand A virus to al­low for a drop of ef­fi­ca­cy on the vari­ants while still of­fer­ing herd im­mu­ni­ty.

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.